In a cohort study, veterans (n=3593) with NSCLC treated with a checkpoint inhibitor, either an anti-PD1 or anti-PDL1 antibody, were evaluated for fibrate exposure (32). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.